point-counterpoint: oncotype dx genomic prostate score in active surveillance – canary pass study
Published 4 years ago • 1.1K plays • Length 17:45Download video MP4
Download video MP3
Similar videos
-
16:11
point-counterpoint q&a w/ dr. lin: oncotype dx genomic prostate score in active surveillance
-
8:07
point-counterpoint q&a w/ dr. klein: oncotype dx genomic prostate score in active surveillance
-
9:15
point-counterpoint: active surveillance for intermediate-risk prostate cancer - pro
-
9:59
point-counterpoint: active surveillance for intermediate-risk prostate cancer - con
-
1:45
dr. febbo explains the oncotype dx genomic prostate score
-
53:50
localized prostate cancer cases - 2021 prostate cancer patient conference
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
29:23
how should we monitor patients during surveillance?
-
28:33
active surveillance results and implications of prospective studies
-
2:25
dr. katz on the oncotype dx gps assay in prostate cancer
-
5:15
point-counterpoint: will conventional imaging become obsolete?–pro
-
11:36
point-counterpoint: will conventional imaging become obsolete? – con
-
5:38
decipher, selectmdx, and 4k score in active surveillance & intermediate prostate cancer | pcri
-
20:39
active surveillance or: shrinking the gray zone
-
20:48
point-counterpoint: management of mcrpc
-
47:00
the canary prostate active surveillance study (pass): cohort development, outcome modeling...
-
20:44
active surveillance 2021 (part 3) - patient selection, monitoring, and innocuous interventions
-
2:09:29
novel tools in the active surveillance for prostate cancer_compress
-
6:18
updates of changes in the early detection of prostate cancer nccn guidelines 2021
-
0:50
oncotype dx® prostate cancer
-
12:46
what role do markers play in establishing active surveillance or definitive care?
-
18:36
update on prostatectomy versus observation trials